Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Xiamen Amoytop Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	449.45	371.82	412.96	301.24	285.42	197.16
Trading Asset Securities	376.07	289.96	257.08	270.78	196.38	268.22
Cash & Short-Term Investments	825.52	661.79	670.04	572.02	481.8	465.38
Cash Growth	41.22%	-1.23%	17.14%	18.73%	3.53%	126.04%
Accounts Receivable	902.74	808.52	441.02	223.05	206.28	185
Other Receivables	38.99	22.34	17.87	20.17	21.67	11.99
Receivables	941.73	830.86	458.9	243.22	227.94	196.99
Inventory	374.64	263.55	187.02	129.73	116.49	99.62
Other Current Assets	92.71	70.9	24.24	10.64	8.19	10.81
Total Current Assets	2,235	1,827	1,340	955.61	834.42	772.8
Property, Plant & Equipment	896.94	686.76	490.85	389.77	192.92	126.74
Other Intangible Assets	378.65	170.85	191.54	121.69	146.91	172.28
Long-Term Deferred Tax Assets	79.54	69.09	43.66	47.18	34.96	24.97
Long-Term Deferred Charges	46.31	221.2	176.7	229.25	169.14	78.24
Other Long-Term Assets	85.71	75.35	112.98	26.05	44.99	16.24
Total Assets	3,786	3,050	2,356	1,770	1,424	1,193
Accounts Payable	83.64	57.76	39.73	50.91	8.14	7.15
Accrued Expenses	152.28	233.75	244.46	159.55	120.4	60.94
Short-Term Debt	19.94	-	-	-	10	18.92
Current Portion of Leases	12.6	5.67	4.16	4.18	5.79	-
Current Income Taxes Payable	47.89	50.27	48.95	41.97	24.42	8.73
Current Unearned Revenue	55.46	63.13	60.05	7.23	5.18	3.34
Other Current Liabilities	209.66	10.06	6.31	4.05	3.3	15.86
Total Current Liabilities	581.47	420.63	403.66	267.89	177.23	114.94
Long-Term Leases	14.51	3.27	3.76	5.56	9.37	-
Long-Term Unearned Revenue	37.22	32.96	40.62	47.68	51.25	56.84
Long-Term Deferred Tax Liabilities	9.28	0.93	0.41	15.15	5.54	3.07
Other Long-Term Liabilities	40.51	39.31	31.25	25.99	19.53	17.48
Total Liabilities	776.99	497.1	479.69	362.27	262.91	192.33
Common Stock	406.8	406.8	406.8	406.8	406.8	406.8
Additional Paid-In Capital	455.26	413.14	397.04	397.04	397.04	397.04
Retained Earnings	2,147	1,733	1,073	603.76	357.42	196.56
Shareholders' Equity	3,009	2,553	1,876	1,408	1,161	1,000
Total Liabilities & Equity	3,786	3,050	2,356	1,770	1,424	1,193
Total Debt	141.05	8.94	7.92	9.74	25.16	18.92
Net Cash (Debt)	684.47	652.85	662.11	562.28	456.63	446.46
Net Cash Growth	19.11%	-1.40%	17.76%	23.14%	2.28%	206.23%
Net Cash Per Share	1.68	1.60	1.63	1.39	1.13	1.11
Filing Date Shares Outstanding	406.8	406.8	406.8	406.8	406.8	406.8
Total Common Shares Outstanding	406.8	406.8	406.8	406.8	406.8	406.8
Working Capital	1,653	1,406	936.53	687.72	657.19	657.86
Book Value Per Share	7.40	6.28	4.61	3.46	2.85	2.46
Tangible Book Value	2,566	2,382	1,685	1,286	1,014	828.12
Tangible Book Value Per Share	6.31	5.86	4.14	3.16	2.49	2.04
Buildings	-	291.61	135.53	118.65	21.31	22.03
Machinery	-	392.63	319.97	271.83	177.83	173.49
Construction In Progress	-	181.56	183.72	135.81	118	68.43

Source: S&P Global Market Intelligence. Standard template. Financial Sources.